Analyst Jason Kolbert Maintains Buy Rating for Pulmonx (LUNG) at $14 Target | LUNG Stock News
D. Boral Capital analyst Jason Kolbert has reaffirmed a Buy rating for Pulmonx (LUNG) with an unchanged price target of $14.00 USD. This decision reflects continued confidence in the medical technology company, which specializes in minimally invasive treatments for severe emphysema. Other analysts have made varying adjustments to their ratings and price targets over the past few months, with the average target price from six analysts currently at $5.75, suggesting a significant upside from its current price.
Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out?
Pulmonx Corp (PULM) has agreed to an all-cash takeover, leading to a sharp rise in its stock price. For current shareholders, the decision is whether to accept the cash offer or to hold out for a potentially higher bid, recognizing that the stock now functions as a merger arbitrage play rather than a growth stock. The acquisition offers a premium, but caps further upside, shifting the investment focus to the deal's closing probability and associated risks.
Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out?
Pulmonx Corp (NASDAQ: PULM) has agreed to an all-cash takeover, leading to a sharp rise in its stock price. For investors, the decision is now whether to accept the fixed cash offer or speculate on a higher bid, transforming the investment into a merger arbitrage situation. The deal, driven by scale, distribution synergies, and regulatory leverage, highlights a trend of innovative small-cap medtech companies exiting public markets through acquisition.
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares?
Pulmonx, a small-cap lung-health specialist known for its Zephyr Valve, has seen its stock price significantly decline over the past year due to reimbursement challenges and execution issues. The company's recent quarterly results showed revenue growth but also highlighted ongoing operating losses and the need for continued investment. Despite underlying clinical backing for its technology, the stock's future hinges on improved reimbursement, operational execution, and capital discipline, leaving investors at a crossroads between a potential turnaround and a value trap.
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares?
Pulmonx, a small-cap lung-health specialist known for its Zephyr Valve, is experiencing significant stock price pressure, trading near its 52-week lows. The decline is attributed to a mix of reimbursement risks, execution challenges, and a broader market rotation away from smaller, unprofitable growth companies. Despite respectable revenue growth, investors remain cautious due to ongoing operating losses and a slow path to profitability, with analysts generally holding a "Hold" or "Market Perform" stance.
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%
Pulmonx Corporation's shares have fallen by 29% in the last month, contributing to a 79% decline over the past year. The company's price-to-sales (P/S) ratio of 0.7x is significantly lower than the industry average, likely due to analyst forecasts predicting revenue growth of 17% annually, which is considerably less than the industry's projected 124% growth. This lower growth expectation seems to be the primary reason for investor pessimism and the depressed P/S ratio.
Pulmonx Q4 2025 Results: A Litmus Test for New Leadership
Pulmonx Corp. is preparing to release its Q4 2025 financial results in late February, with investors keen to assess if the company met its annual revenue targets of $89-90 million and how its new leadership team, including CEO Glen French and COO/CFO Derrick Sung, has performed. The market will specifically focus on revenue breakdown by geography, following a trend in Q3 2025 where international growth outpaced the U.S. market, and the overall trajectory of the medical technology firm.
Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet?
Pulmonx Corporation (NASDAQ:LUNG) has a healthy balance sheet, boasting net cash of US$39.4m against its debt of US$37.1m as of September 2025. While the company is unprofitable, with an EBIT loss and negative free cash flow, its strong cash position provides liquidity for growth. However, investors should remain cautious due to the company's lack of profitability and consider additional warning signs before making investment decisions.
Pulmonx Navigates Leadership Shift Amidst Mixed Financial Results
Pulmonx Corp (US7458481014) is experiencing significant price volatility following a mixed Q3 2025 earnings report and executive changes. The company saw 5% global revenue growth to $21.5 million, primarily from international markets, but reported a net loss of $14.0 million. Amidst a revised annual revenue outlook, Glen French returned as CEO and Derrick Sung became COO/CFO, while diverging insider transactions have raised questions.
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified
Pulmonx Corporation's stock has seen a 26% increase over the last month, but this follows a 67% decline over the past year. Despite a low price-to-sales (P/S) ratio of 1x compared to an industry average of 3.5x, the company's future revenue growth forecast of 17% annually for the next three years is significantly lower than the industry's predicted 138% growth. This disparity in growth expectations is likely contributing to the suppressed P/S ratio, indicating that improved revenue performance is needed to justify a higher valuation.
Pulmonx (Nasdaq: LUNG) issues 1,625,000-share inducement grants, incl. 1.6M RSUs/PSUs
Pulmonx Corporation announced that it granted equity awards totaling 1,625,000 shares to two new executives, including CFO Derrick Sung, under its 2025 Inducement Plan. The grants comprise 1,225,000 Restricted Stock Units (RSUs) and up to 400,000 Performance Stock Units (PSUs) for Sung, subject to both time-based and performance vesting conditions. These awards were made to incentivize the new hires and comply with Nasdaq Listing Rule 5635(c)(4).
Pulmonx Corporation Grants 1,625,000 Equity Awards as Part of 2025 Inducement Plan
Pulmonx Corporation has granted 1,625,000 equity awards, including restricted stock units (RSUs) and performance stock units (PSUs), to new hires under its 2025 Inducement Plan. Chief Financial Officer Derrick Sung received a significant portion of these awards, which are designed to attract and retain talent and are subject to vesting conditions based on time and performance. This move aims to align executive compensation with shareholder interests and support Pulmonx's strategic direction as a leader in minimally invasive treatments for chronic obstructive pulmonary disease.
Pulmonx CEO French sells $13.8k in LUNG stock
Pulmonx Corp CEO Glendon E. French III sold 8,805 common shares for approximately $13,823 to cover tax obligations related to vesting Restricted Stock Units (RSUs). French also acquired 1,200,000 RSUs and 800,000 Performance Stock Units, significantly increasing his holdings. The company, a micro-cap medical device firm, appears undervalued despite not being profitable in the last twelve months, holding more cash than debt but burning through reserves.
Pulmonx stock rating reiterated at Buy by Stifel after 3Q results
Stifel has reiterated its Buy rating and $5.00 price target for Pulmonx Corp. (NASDAQ:LUNG) following the company's Q3 2025 earnings report. This rating comes despite lowered full-year sales guidance, as the company beat expectations for EPS and revenue, and new management aims for accelerated profitable growth. InvestingPro data also suggests the stock is currently undervalued with a significant revenue growth over the last year.
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
Pulmonx (NASDAQ: LUNG) announced the reappointment of Glen French as President and CEO and Derrick Sung as COO and CFO, effective November 3, 2025, following the resignations of two executives. The company also reported preliminary, unaudited Q3 2025 revenue of approximately $21.5 million and rescheduled its Q3 earnings call to November 12, 2025. This leadership change aims to ensure stability and capitalize on growth opportunities in minimally invasive lung disease treatments.
Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In?
Pulmonx Corporation (LUNG) is considered one of the best stocks under $3, despite recent price target reductions by analysts. Lake Street and Stifel Nicolaus maintained a Buy rating, while Canaccord Genuity also kept a Buy rating with a higher price target. The company is a commercial-stage medical technology firm offering minimally invasive treatment for severe emphysema.
Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In?
Pulmonx Corporation (NASDAQ: LUNG) is highlighted as a potentially strong investment under $3, despite a recent price target reduction by Lake Street to $4 from $8 while maintaining a Buy rating. Analysts emphasize the company's attractive features, including proven Zephyr valves, significant market potential, and a new product pipeline. Other firms like Stifel Nicolaus and Canaccord Genuity also maintain Buy ratings with price targets of $5 and $6, respectively.
LUNG’s Surprise Revenue Surge: Key Factors
Pulmonx Corporation (NASDAQ: LUNG) experienced a significant stock surge of 34.62% following a Q3 revenue report of $21.5M, surpassing market estimates, and recent leadership changes. Despite encouraging revenue growth and a strong market response, the company faces profitability challenges with negative margins and return on assets. The article emphasizes observing both growth potential and financial pitfalls for LUNG's future trajectory.
Pulmonx brings back former CEO amid leadership shakeup
Pulmonx Corporation has reappointed Glen French as President and CEO, replacing Steve Williamson, and named former CFO Derrick Sung as COO and CFO. This leadership change comes as the company faces a nearly 75% stock drop over the past year and downward revised earnings expectations from analysts. Despite these challenges, Pulmonx reported an 18% year-over-year revenue growth in Q3 2025 and maintains a strong current ratio and net cash position, though profitability challenges persist.
Oct. 29, 2025: Pulmonx to Release Third Quarter Results; Webcast and Conference Call Available - Stock Titan
Pulmonx (Nasdaq: LUNG) announced it will release its third-quarter 2025 financial results on Wednesday, October 29, 2025, after market close. The company's management will host a conference call and webcast on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Interested participants need to register online to receive call-in details.
Jaeger™ and Pulmonx Announce Strategic Partnership to Integrate Data Qualification Capabilities into SentrySuite™
Jaeger™ Medical and Pulmonx Corporation have announced a strategic partnership to integrate advanced data qualification functionality into Jaeger's SentrySuite™ software platform. This collaboration aims to enhance the platform's ability to support consistent clinical decision-making by enabling healthcare providers to identify patients who may qualify for innovative treatments like the Zephyr Valve. The integration will streamline how clinicians interpret and act on respiratory diagnostic data, particularly for conditions like severe hyperinflation secondary to emphysema.
Pulmonx Corporation Announces Participation in Upcoming Investor Conferences | LUNG Stock News
Pulmonx Corporation announced its participation in the Wells Fargo Healthcare Conference and the Lake Street Best Ideas Growth Conference in September 2025. The company will present its innovative lung disease treatments, including the FDA-approved Zephyr® Endobronchial Valve. The article also details recent insider trading activity, hedge fund movements, and analyst ratings and price targets for LUNG stock.
Lung Disease Treatment Leader Pulmonx (LUNG) Sets Two Major Investor Conference Appearances in September
Pulmonx (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, announced its participation in two investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference in Boston on September 4 and will hold one-on-one meetings at the Lake Street Best Ideas Growth Conference in New York on September 11. Webcasts for the Wells Fargo conference will be available on Pulmonx's investor relations website.
Earnings call transcript: Pulmonx reports Q2 2025 revenue beat, stock gains
Pulmonx Corp (NASDAQ: LUNG) reported a Q2 2025 revenue beat of $23.9 million, surpassing expectations, and a narrower-than-forecasted net loss of $0.38 per share, leading to a 1.94% stock increase. Despite revising its full-year 2025 revenue guidance downward to $90-92 million due to slower U.S. initiative ramp-up, the company highlighted strong international growth and progress in its "acquire, test, and treat" strategy to expand market reach and patient identification. The CEO emphasized confidence in long-term growth by building an ecosystem for treating severe emphysema patients.
Shareholders May Not Overlook Pulmonx Insiders Selling US$670k In Stock
Pulmonx Corporation (NASDAQ:LUNG) saw its stock gain 17% last week, but insiders who sold US$670k worth of stock at an average price of US$5.57 over the past year appear to have made a good decision, as the current price is lower. The article highlights that overall, insiders sold more shares than they bought, with a net sale price above the current trading price. Despite some insider buying, the recent trend shows more selling than buying, and the insider ownership is considered low at 2.6% of the stock.
Pulmonx stock plunges to 52-week low of $3.17 amid market challenges
Pulmonx (NASDAQ: LUNG) stock has fallen to a 52-week low of $3.17, reflecting negative investor sentiment despite strong liquidity and 19.84% revenue growth over the past year. Analysts from Stifel and Canaccord Genuity maintain a Buy rating, citing potential U.S. sales growth and long-term prospects, particularly with international expansion efforts in China. The company's Q1 2025 earnings showed a narrower-than-expected loss per share and reaffirmed full-year revenue guidance.
Hyperpolarized gas MRI for pulmonary diagnostics | Clinical Briefing
Pulmonologists at the Penn Lung Center are investigating hyperpolarized gas 129Xe MRI as a diagnostic tool for optimizing endobronchial valve placement in COPD patients. This MRI technique allows for direct visualization of regional lung ventilation and gas exchange, offering an advancement over traditional imaging methods that carry radiation risks. A case study demonstrates the effectiveness of HXe MRI in guiding treatment and assessing physiological changes post-procedure, showing significant improvements in lung function and gas exchange.
A New Report Confirms Significant Benefits in Patient Reported Outcomes at One Year Following the Non-Surgical Zephyr Valve Procedure for COPD/Emphysema
A new report published in the Annals of the American Thoracic Society confirms the Zephyr Valve's effectiveness in improving patient-reported outcomes for COPD/emphysema patients. The analysis of the LIBERATE Study data showed statistically significant improvements in breathlessness, activity levels, and quality of life a year after treatment. Pulmonx, the manufacturer, highlights that the Zephyr Valve breaks the cycle of limited exercise and social activity, significantly enhancing patients' well-being.
Pulmonx Secures $66 Mln In Financing To Support Commercial Acceleration Of The Zephyr Valve System
Pulmonx Corp has secured $66 million in financing to accelerate the commercialization of its Zephyr Valve System, a minimally-invasive treatment for severe emphysema. The financing was led by Ally Bridge Group, with an additional $17 million in growth capital from CIBC Innovation Banking to refinance existing debt.
The National Institute for Health and Care Excellence (NICE) Updated Guidance on Endobronchial Valves: What Was Behind the Decision and What Does it Mean for Pulmonologists?
The National Institute for Health and Care Excellence (NICE) has updated its guidance to support the routine use of endobronchial valve therapy for emphysema, aligning with other global health organizations. This decision is significant for pulmonologists and emphysema patients, as it acknowledges the efficacy and safety of bronchoscopic lung volume reduction (BLVR) with valves as a less invasive treatment option compared to surgery. The article details the clinical evidence, patient selection criteria, and potential benefits and risks associated with endobronchial valves like the Zephyr® Endobronchial Valve, emphasizing its role in improving lung function and quality of life for severely affected patients.
FDA Approves Endobronchial Valves for Severe Emphysema
The FDA has approved the Zephyr Endobronchial Valve System by Pulmonx Corp. for treating severe emphysema. This minimally-invasive device, the first of its kind in the US, offers a significant improvement over previous treatment options by reducing hyperinflation and improving quality of life for patients. The approval was based on positive clinical data, including the LIBERATE Study, highlighting its breakthrough technology and clinical advantages.
